ClinicalTrials.gg
RecruitingNCT03947385Updated Jun 8, 2026

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

A Phase 1/2 interventional study of IDE196 and Binimetinib in Metastatic Uveal Melanoma, Cutaneous Melanoma and Colorectal Cancer, sponsored by IDEAYA Biosciences. Recruiting at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by IDEAYA Biosciences · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
336
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 190 studies in Uveal Melanoma with a site in United States — 25 open to participants now, 50 under way, 7 of them phase 3. Uveal Melanoma · United States.

Planned enrollment
8th of 162
336 · median 36
Started
2019
with 8 others
Phase 1/2
20 of 190
7 open now
Primary completion
2027-01
later than 15 of 49 live
Registered
130th of 190
by date
Lead sponsor
5 of 190
IDEAYA Biosciences

Among the 190 studies in Uveal Melanoma with a site in United States, this one is the 8th largest by planned enrollment of the 162 interventional ones that give a count, is one of 9 that started in 2019, is one of 20 in phase 1/2, reaches primary completion later than 15 of the 49 other live ones, and was the 130th registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

25 of the 190 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Uveal Melanoma studies recruiting now, 35 (83%) set no upper age limit and 4 (10%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Uveal Melanoma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors.

Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.

Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study.

Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study.

Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity.

As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.

03

Conditions studied

  • Metastatic Uveal Melanoma
  • Cutaneous Melanoma
  • Colorectal Cancer
  • Other Solid Tumors

Keywords

  • Metastatic Uveal Melanoma
  • Uveal Melanoma
  • Protein Kinase C
  • Ophthalmology
  • Ocular Oncology
  • Darovasertib
  • IDE196
  • Ocular Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be ≥18 years of age and able to provide written
  • Diagnosis of the following:

    o MUM: Uveal melanoma with histological or cytological confirmed disease. Metastatic disease may be treatment naïve or have progressed on or after most recent therapy. If the most recent therapy was an immune-oncology agent, PD must be confirmed.

    - If a patient is treatment naïve and human leukocyte antigen (HLA)-A*02:01 positive***, documentation is required to provide rationale why treatment with tebentafusp is not the ideal firstline treatment approach or of the patient's intolerance to tebentafusp.

    ***To be enrolled in the HLA-A*02:01 positive cohort, HLA status must be documented by test results from a CAP/CLIA-certified laboratory.

  • per v1.1
  • ≤1 and expected of > 3 months
  • Adequate organ function at screening
  • Adequate measures for non-sterilized male and female patients of

Crizotinib Combination Additional Inclusion Criteria:

  • Prior chemotherapy other therapies as applicable or major surgeries must have been completed at least 4 weeks prior to initiation of crizotinib
  • Patients with preexisting peripheral neuropathy can be included if it is Grade 1 or lower, prior to initiation of crizotinib -eligible patients
  • Accessible lesion(s) that permit a total of at least two biopsies without unacceptable risk of a significant procedural complication.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with a PKC inhibitor
  • Known MSI-H/dMMR tumors who have not previously received
  • Known symptomatic
  • Adverse events from prior anti-cancer therapy that have not resolved
  • Known acquired immunodeficiency syndrome (AIDS)-related illness, virus, or virus
  • Active infection requiring ongoing therapy
  • Recent surgery or radiotherapy
  • Prior gastrectomy or upper bowel removal or any other gastrointestinal disorder or defect
  • Females who are pregnant or breastfeeding
  • Impaired cardiac function
  • Treatment with prohibited medications that cannot be discontinued prior to study entry
  • For patients receiving IDE196 powder-in-capsule (PIC) formulation or crizotinib, allergy to mammalian meat products and gelatin

Crizotinib Combination Additional Exclusion Criteria:

  • Prior therapy directly targeting ALK, MET, or ROS1
  • Spinal cord compression
  • History of pneumonitis or interstitial lung disease
  • History of syncope
  • History of thromboembolic or cerebrovascular events ≤12 weeks prior to first dose of study treatment

PK Substudy (optional) with Pravastatin Additional Exclusion Criteria:

  • Taken any dose of statin or inhibitor of organic anion transporting polypeptide within 7 days prior to enrollment in the study and cannot refrain from them through C2D1
  • Taken drugs that interfere with the absorption, metabolism, or elimination of pravastatin
  • Any associated to the use of statins or component of pravastatin
  • Active liver disease

DDI Cocktail Substudy Additional Exclusion Criteria:

  • Treatment with bupropion, repaglinide, flurbiprofen, omeprazole, esomeprazole, midazolam, and dabigatran etexilate within 7 days prior to Cycle 1 Day -1.
  • Intake of vitamin supplements containing Vitamin B6 (pyridoxine), grapefruit/grapefruit juice, or Seville orange juice within 7 days prior to Cycle 1 Day -1.
  • Intake of any strong or moderate inhibitor of CYP2B6, CYP2CI, CYP2C9, CYP2C10 and OAT3 is prohibited within 7 days or within 5 half-lives, whichever is longer, of Cycle 1 Day -1.
  • Moderate and strong inhibitors of CYP2A4/5 or P-gp are prohibited within 7 days, or within 5 half-lives, whichever is longer, of Cycle 1 Day -1.
  • Intake of strong or moderate inducers of /5, CYP2B6, CYP2C9, CYP2C19, or OAT3 is prohibited during 15 days, or 5 half-lives, whichever is longer, prior to Cycle 1 Day -1.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
336 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Monotherapy (Enrollment Complete)

    IDE196 dosed orally, twice daily (BID) for each 28-day cycle

    Drug: IDE196

  • Experimental
    Dose Expansion Monotherapy (Enrollment Complete)

    RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations or PRKC fusions (cutaneous melanoma, CRC, other solid tumors)

    Drug: IDE196

  • Experimental
    Dose Escalation Binimetinib Combination (Enrollment Complete)

    IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Binimetinib dosed orally, twice daily (BID) for each 28-day cycle

    Drug: IDE196 · Drug: Binimetinib

  • Experimental
    Dose Expansion Binimetinib Combination (Enrollment Complete)

    RP2D in MUM and non-MUM tumors harboring GNAQ/11 mutations (cutaneous melanoma, CRC, other solid tumors)

    Drug: IDE196 · Drug: Binimetinib

  • Experimental
    Dose Escalation Crizotinib Combination (Enrollment Complete)

    IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle

    Drug: IDE196 · Drug: Crizotinib

  • Experimental
    Dose Expansion Crizotinib Combination (Enrolling)

    MUM patients (previously treated or treatment naive) with human leukocyte antigen (HLA)-A\*02:01 positive status. Includes a nested PK sub-study with Pravastatin (\~22 participants) to evaluate the impact of pravastatin PK profiles after continuous dosing of IDE196. Includes a nested PK Cocktail DDI sub-study (\~15 participants) to evaluate the impact on the PK of bupripion, repaglinide, flurbiprofen, omeprazole, midazolam, dabigatran etexilate, and the exposures of the OAT3 biomarker PDA by IDE196 in combination with crizotinib.

    Drug: IDE196 · Drug: Crizotinib

  • Experimental
    Dose Optimization Crizotinib Combination (Enrollment Complete)

    IDE196 dosed orally, twice daily (BID) for each 28-day cycle and Crizotinib dosed orally, twice daily (BID) for each 28-day cycle

    Drug: IDE196 · Drug: Crizotinib

  • Experimental
    Crizotinib Monotherapy with Crossover to Combination (Enrollment Complete)

    Crizotinib dosed orally, twice daily (BID) for each 28-day cycle until disease progression then IDE196 added and dosed orally, twice daily (BID) for each 28-day cycle

    Drug: IDE196 · Drug: Crizotinib

Interventions

  • DrugIDE196

    IDE196 dosed orally, twice daily for each 28-day cycle

    Also known as: Protein Kinase C (PKC) Inhibitor

  • Binimetinib dosed orally, twice daily for each 28-day cycle

    Also known as: MEKTOVI

  • Crizotinib dosed orally, twice daily for each 28-day cycle

    Also known as: XALKORI

06

What researchers measure

Primary outcomes

  1. Dose-limiting Toxicity (DLT)

    Determine DLT of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

    Time frame: 28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

  2. Incidence of Adverse Events

    Safety and tolerability of IDE196 either as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

    Time frame: Approx. 8 months

  3. Maximum Tolerated Dose (MTD)

    Determine MTD of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

    Time frame: 28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

  4. Recommended Phase 2 Dose (RP2D) as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

    Determine RP2D of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

    Time frame: Approx. 6 months

  5. Plasma Concentrations of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

    Pharmacokinetics of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib

    Time frame: Approx. 6 months

  6. Plasma Concentrations of Crizotinib administered in combination with IDE196

    Pharmacokinetics of Crizotinib in combination with IDE196

    Time frame: Approx. 6 months

  7. Plasma Concentrations of Binimetinib administered in combination with IDE196

    Pharmacokinetics of Binimetinib in combination with IDE196

    Time frame: Approx. 6 months

  8. Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment

    Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) criteria

    Time frame: Approx. 8 months

  9. Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment

    RECIST v1.1

    Time frame: Approx. 8 months

Secondary outcomes

  1. Progression Free Survival (PFS) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessment

    RECIST v1.1

    Time frame: Approx. 18 months

  2. Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts and by prior treatment status (pretreated or treatment naive) by Investigator response assessment

    Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) criteria

    Time frame: Approx. 18 months

  3. Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by prior treatment status (pretreated or treatment naive) by Investigator response assessment

    RECIST v1.1

    Time frame: Approx. 18 months

  4. Disease Control Rate (DCR) by Investigator

    RECIST v1.1

    Time frame: Approx. 18 months

  5. Area under the plasma concentration versus time curve (AUC)

    PK parameters of bupropion, hydroxybupropion, repaglinide, flurbiprofen, omeprazole, midazolam, total dabigatran (dabigtran+glucuronide), and the exposures of PDA (as data permits)

    Time frame: Approx. 8 months

  6. Area under the plasma concentration curve from time zero extrapolated to infinity (AUCinf)

    PK parameters of bupropion, hydroxybupropion, repaglinide, flurbiprofen, omeprazole, midazolam, total dabigatran (dabigtran+glucuronide), and the exposures of PDA (as data permits)

    Time frame: Approx. 8 months

  7. Area under the plasma concentration curve from time zero to the last measurable concentration time (AUC0-t)

    PK parameters of bupropion, hydroxybupropion, repaglinide, flurbiprofen, omeprazole, midazolam, total dabigatran (dabigtran+glucuronide), and the exposures of PDA (as data permits)

    Time frame: Approx. 8 months

  8. Area under the plasma concentration curve extrapolating the percentage of total drug exposure (AUC%extra)

    PK parameters of bupropion, hydroxybupropion, repaglinide, flurbiprofen, omeprazole, midazolam, total dabigatran (dabigtran+glucuronide), and the exposures of PDA (as data permits)

    Time frame: Approx. 8 months

  9. Peak Plasma Concentration (Cmax)

    PK parameters of bupropion, hydroxybupropion, repaglinide, flurbiprofen, omeprazole, midazolam, total dabigatran (dabigtran+glucuronide), and the exposures of PDA (as data permits)

    Time frame: Approx. 8 months

  10. Time to maximum plasma concentration (Tmax)

    PK parameters of bupropion, hydroxybupropion, repaglinide, flurbiprofen, omeprazole, midazolam, total dabigatran (dabigtran+glucuronide), and the exposures of PDA (as data permits)

    Time frame: Approx. 8 months

  11. Elimination half-life of Plasma Concentration levels (T1/2)

    PK parameters of bupropion, hydroxybupropion, repaglinide, flurbiprofen, omeprazole, midazolam, total dabigatran (dabigtran+glucuronide), and the exposures of PDA (as data permits)

    Time frame: Approx. 8 months

Other outcomes

  1. Overall Survival

    From date of First Dose to End of Follow-up

    Time frame: Approx. 18 months

  2. Anti-tumor activity (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Blinded Independent Review Committee (BICR)

    RECIST v1.1

    Time frame: Approx. 18 months

  3. Anti-tumor activity (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Blinded Independent Review Committee (BICR)

    RECIST v1.1

    Time frame: Approx. 18 months

  4. Anti-tumor activity (PFS) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Blinded Independent Review Committee (BICR)

    RECIST v1.1

    Time frame: Approx. 18 months

  5. Anti-tumor activity (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in phase 1 Dose Escalation cohorts by Investigator response assessment

    RECIST v1.1

    Time frame: Approx. 18 months

  6. Anti-tumor activity (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in phase 1 Dose Escalation cohorts by Investigator response assessment

    RECIST v1.1

    Time frame: Approx. 18 months

  7. Anti-tumor activity (DCR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in phase 1 Dose Escalation cohorts by Investigator response assessment

    RECIST v1.1

    Time frame: Approx. 18 months

  8. Anti-tumor activity (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in pre-treated participants by Investigator response assessment

    RECIST v1.1

    Time frame: Approx. 18 months

  9. Anti-tumor activity (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in pre-treated participants by Investigator response assessment

    RECIST v1.1

    Time frame: Approx. 18 months

  10. Anti-tumor activity (DCR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in pre-treated participants by Investigator response assessment

    RECIST v1.1

    Time frame: Approx. 18 months

  11. Treatment-related gene signatures and/or molecular profiling

    Modulation of gene signatures and/or molecular profiles

    Time frame: Approx. 18 months

  12. Treatment-related pharmacodynamic effect in all patients

    Modulation of signaling proteins in the PKC pathway (eg, PKC-delta), the MAPK pathway (eg, MEK and extracellular signal-regulated kinase \[ERK\]) and the MET pathway (eg, MET)

    Time frame: Approx. 18 months

  13. Treatment-related changes in tumor tissue or cell-free DNA from blood

    Exploratory assessment of treatment-related changes in tumor tissue or cell-free DNA from blood across treatment doses and ORR per RECIST v1.1

    Time frame: Approx. 18 months

  14. Metabolite profile of IDE196 in plasma

    Exploratory assessment of IDE196 metabolite profiling the plasma

    Time frame: Approx. 18 months

  15. PK parameters of pravastatin (as data permits) including the area under the plasma concentration versus time curve (AUC)

    Impact on pravastatin PK profile by IDE196 and Crizotinib combination

    Time frame: Approx. 18 months

  16. PK parameters of pravastatin (as data permits) including the area under the plasma concentration curve from time zero extrapolated to infinity (AUCinf)

    Impact on pravastatin PK profile by IDE196 and Crizotinib combination

    Time frame: Approx. 18 months

  17. PK parameters of pravastatin (as data permits) including the area under the plasma concentration curve from time zero to the last measurable concentration time (AUC0-t)

    Impact on pravastatin PK profile by IDE196 and Crizotinib combination

    Time frame: Approx. 18 months

  18. PK parameters of pravastatin (as data permits) including the area under the plasma concentration curve extrapolating the percentage of total drug exposure (AUC%extra)

    Impact on pravastatin PK profile by IDE196 and Crizotinib combination

    Time frame: Approx. 18 months

  19. PK parameters of pravastatin (as data permits) including the peak plasma concentration (Cmax)

    Impact on pravastatin PK profile by IDE196 and Crizotinib combination

    Time frame: Approx. 18 months

  20. PK parameters of pravastatin (as data permits) including the time to maximum plasma concentration (Tmax)

    Impact on pravastatin PK profile by IDE196 and Crizotinib combination

    Time frame: Approx. 18 months

  21. PK parameters of pravastatin (as data permits) including the Elimination half-life of Plasma Concentration levels (T1/2)

    Impact on pravastatin PK profile by IDE196 and Crizotinib combination

    Time frame: Approx. 18 months

07

Study locations

7 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2019 (actual). Primary completion is estimated for Jan 2027, 91 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2019
First posted
May 13, 2019
StartActual
Jun 28, 2019
Primary completionEst.
Jan 29, 2027
CompletionEst.
Jun 15, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03947385
Lead sponsor
IDEAYA Biosciences
Responsible party
Sponsor
First posted
May 13, 2019
Start date
Jun 28, 2019
Primary completion
Jan 29, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

IDEAYA Clinical Trials
Contact
IDEAYAClinicalTrials@ideayabio.com
855-IDEA-BIO (855-433-2246)
George Cole Jr., MD
study director · gcole@ideayabio.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darovasertib

Start the discussion